Verified ComparisonLast updated: 19 April 2026
Mod GRF 1-29 vs Tesamorelin
Tesamorelin is a lipophilic GHRH analog approved in some countries for metabolic lipodystrophy. Mod GRF 1-29 is a shorter-acting modified fragment.
Mod GRF 1-29
GH Releasing
4.2/ 5
A−
Tesamorelin
GH Releasing
4.3/ 5
A−
Editor's note
Tesamorelin has clinical approval and depot formulations; Mod GRF 1-29 offers higher dosing precision.
| Criterion | Mod GRF 1-29 | Tesamorelin |
|---|---|---|
| Duration | Hours (short) | Hours to days (longer) |
| Regulatory approval | Investigational | Approved in some jurisdictions |
| Clinical evidence | Preclinical-focused | Clinical trials (lipodystrophy) |
| Dosing frequency | Daily or multiple daily | Less frequent |
| Research application breadth | Broad GH secretion | Specific (lipid metabolism) |
Frequently asked questions
Tesamorelin has clinical trials; Mod GRF 1-29 is primarily in research contexts.
Want to read the full reviews?